In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

New onset atrial fibrillation in acute coronary syndrome: early vs late onset

Session Blockbusters from the Young in coronary artery disease

Speaker Jose Pedro Alves Guimaraes

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease and Comorbidities
  • Session type : Abstract Session
  • FP Number : 4183

Authors : J Alves Guimaraes (Vila Real,PT), FM Goncalves (Vila Real,PT), S Borges (Vila Real,PT), JJ Monteiro (Vila Real,PT), PS Mateus (Vila Real,PT), J Trigo (Vila Real,PT), JI Moreira (Vila Real,PT)

J Alves Guimaraes1 , FM Goncalves1 , S Borges1 , JJ Monteiro1 , PS Mateus1 , J Trigo1 , JI Moreira1 , 1Hospital Center of Tras-os-Montes and Alto Douro - Vila Real - Portugal ,

On behalf: Portuguese Registry on Acute Coronary Syndromes


The prognostic impact of the timing where new-onset Atrial Fibrillation (AF) occurs in Acute Coronary Syndrome (ACS) patients isn't well studied.

Evaluate the predictors and prognostic impact of early-onset AF (EAF) and late-onset AF (LAF) in ACS patients.

We analysed 17016 patients with ACS enrolled in a national multicenter registry from October 2010 to January 2019. Patients with history of valvular disease, valve replacement, AF present at hospital admission or those who died in the first 48 hours were excluded. EAF was defined as AF in the first 48 hours of hospitalization and LAF after 48 hours. The primary endpoint was a composite of death and readmission from cardiovascular causes at 1 year.

The mean age was 65±13 years; 74% were males and 42% had STEMI). 324 (1.9%) had EAF and 344 (2.0%) had LAF.
The predictors of EAF were age =75 years (OR 2.04, 95%CI 1.53-2.70, p<.001); history of heart failure (OR 1.82, 95%CI 1.09-3.02, p=.022), STEMI diagnosis (OR 2.74, 95%CI 2.06-3.61, p<.001), admission Killip class (KK)=2 (OR 2.70, 95%CI 1.98-3.69, p<.001).
The predictors of LAF were age =75 years (OR 3.15, 95%CI 2.36-4.19, p<.001), history of stable angina (OR 1.42, 95%CI 1.06-1.90, p=.018), cerebrovascular disease (OR 1.68, 95%CI 1.14-2.46, p=.008), COPD (OR 2.33, 95%CI 1.58-3.44, p<.001), STEMI diagnosis (OR 2.31, 95%CI 1.77-3.03, p<.001), admission KK =2 (OR 2.06, 95%CI 1.54-2.76, p<.001) and stress hyperglycemia (OR 1.54, 95%CI 1.15-2.05, p=.003)
In STEMI patients only those with LAF had higher symptoms time (245(IQR 165-400) minutes vs 284(IQR 200-425) min; p=.02).
During hospitalization, LAF patients had a worse prognosis with a higher rate of heart failure, re-infarction, stroke, major bleeding and death (Table 1).

In the follow-up, in multivarite analysis, only LAF was a predictor of the primary endpoint (EAF: HR 0.79, 95%CI 0.50-1.25, p=.314; LAF: HR 1.45, 95%CI 1.05-2.00, p<.025).

Patients with EAF and LAF have different characteristics and outcomes with LAF patients having a worse in-hospital and long term prognosis.

Death 1.3 6.5 12.5 <.001
Heart Failure 11.4 38.3 50.3 <.001
Re-enfarction 1.0 0.9 3.5 <.001
Stroke 0.5 0.9 3.8 <.001
Major bleeding 1.3 4.3 4.1 <.001

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are